

3 September 2025

How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another Trust, and if so which one?

- 1. How many ovarian cancer patients (any stage) have been treated in the last 3 months with?**

Paclitaxel in combination with a platinum-based compound - 29
Platinum-based therapy alone (cisplatin or carboplatin) - 38
Bevacizumab in combination with paclitaxel and carboplatin - 10
Olaparib - 23
Olaparib + Bevacizumab- <5
Niraparib - 59
Rucaparib - <5

- 2. Does your Trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part**

The following study is open to ovarian patients:

The ModiFY Study: A phase 1/2, multicentre, open-label study of Modi-1 in patients with breast, head and neck, ovarian, or renal cancer

<5 recruited to date.

- 3. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:**

Olaparib
Olaparib + Bevacizumab
Niraparib
Other treatments

Not Available - This result from testing is not recorded in RISOH or in Encompass. A report was run from Encompass – this generated no results.

3 September 2025

Where numbers are low we have indicated <5 (less than five) rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.